Economy/Home · Economy

Shin Poong Pharmaceutical Files for Amendment Approval of Phase 3 Trial Plan for Acute Ischemic Stroke Treatment 'SP-8203'... Reflecting Metalyse Information

Shin Poong Pharmaceutical announced in a regulatory filing on the 15th that it has applied to the Ministry of Food and Drug Safety for approval of a protocol amendment for the Phase 3 clinical trial of SP-8203 (Otaplimastat), a treatment for acute ischemic stroke. ■ Phase 3 Trial Enrolling 852 Subj

Oseong Kwon
Staff Reporter
5 min read
Shin Poong Pharmaceutical Files for Amendment Approval of Phase 3 Trial Plan for Acute Ischemic Stroke Treatment 'SP-8203'... Reflecting Metalyse Information
CBC News

Shin Poong Pharmaceutical announced in a regulatory filing on the 15th that it has applied to the Ministry of Food and Drug Safety for approval of a protocol amendment for the Phase 3 clinical trial of SP-8203 (Otaplimastat), a treatment for acute ischemic stroke.

■ Phase 3 Trial Enrolling 852 Subjects... Trial Design

This clinical trial is a multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of SP-8203 injection in patients with acute cerebral infarction receiving standard thrombolytic therapy. The trial is being conducted at multiple institutions, including Gangneung Asan Hospital.

A total of 852 patients will be enrolled, with 426 each assigned to two groups: an SP-8203 injection 40mg/50ml dose group and a placebo group. SP-8203 injection is administered twice daily at a dose of 80mg/day, for a total of six administrations. The first dose is given within 30 minutes after administration of the standard-of-care thrombolytic agent, and efficacy and safety are evaluated based on the proportion of patients with mRS 0-1 assessed at day 90, among other measures.

■ Reason for the Amendment Application

The amendment application was filed to update information on the thrombolytic agent TNK (Metalyse), which has been newly approved as a standard treatment and included in guidelines, following rtPA (Actilyse), the existing standard treatment for cerebral infarction. Specifically, the amendment reflects the precautions and administration methods from the product approval report for Metalyse Injection 25mg, registered with the Ministry of Food and Drug Safety, in the exclusion criteria and clinical trial methods of the SP-8203 Phase 3 protocol.

The Phase 3 clinical trial plan for SP-8203 was submitted on August 9, 2024, and approved on October 14 of the same year. The company stated that it is currently conducting the large-scale Phase 3 trial based on the safety and efficacy results of the Phase 2 study.

■ 'Statistical Probability of Approval Approximately 10%'... Investment Cautions Noted

Shin Poong Pharmaceutical explained in the filing that the statistical probability of a clinical trial drug ultimately receiving drug approval is known to be around 10%. It also noted investment cautions, stating that if the clinical trial and product approval process yields results that fall short of expectations, the company may change or abandon its commercialization plans.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.